The Zhitong Finance App learned that Cornerstone Pharmaceutical-B (02616) rose nearly 7% in early trading. As of press release, it rose 3.39% to HK$5.035, with a turnover of HK$19.219,500.

According to the news, Cornerstone Pharmaceuticals announced that the company's self-developed PD-1/VEGF/CTLA-4 three-specific antibody CS2009 achieved a major clinical validation milestone, and announced the latest clinical data in the form of two quick oral reports at the 2026 European Society of Medical Oncology (ESMO) conference. Relying on clinical data sets from a variety of solid tumors and a total of more than 300 subjects, CS2009 has simultaneously completed three key clinical verifications: mechanism of action verification, safety verification, and clinical concept verification in broad-spectrum tumors.

The latest data on nsCLC and mCRC released by ESMO further consolidates this verification with outstanding efficacy of single drugs and combination treatments — CS2009 showed impressive anti-tumor efficacy in immunotreated people and patients with immune “cold tumors” in the traditional sense. These results form a key point in the substantial reduction in the risk of clinical development of CS2009, and also confirm that its innovative molecular design is expected to break through the limitations of existing tumor immunotherapy.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.